B of A Securities Upgrades West Pharmaceutical Servs to Buy, Raises Price Target to $405
Portfolio Pulse from richadhand@benzinga.com
Bank of America Securities analyst Derik De Bruin upgraded West Pharmaceutical Services (NYSE:WST) from Neutral to Buy and raised the price target from $390 to $405.
June 16, 2023 | 11:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
West Pharmaceutical Services (WST) has been upgraded from Neutral to Buy by BofA Securities, with a raised price target of $405.
The upgrade from Neutral to Buy and the raised price target by BofA Securities analyst Derik De Bruin indicate a positive outlook for West Pharmaceutical Services (WST) in the short term. This news is likely to attract more investors, driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100